FDA approves first drug targeting Alexander disease

· Science · United States

The U.S. Food and Drug Administration has approved Zanvastro, the first drug that directly targets Alexander disease, a rare and fatal neurological disorder that affects fewer than one in a million people. The approval follows decades of research into the condition, which has had no disease-specific treatment. In clinical trials, the drug stabilized motor function in patients and even improved movement in some of them. Alexander disease is caused by mutations that lead to the buildup of a protein in the brain, and it has historically been managed only with supportive care. The decision gives patients and families a first therapy aimed at the underlying disease, and it could encourage further development of treatments for other ultra-rare neurological conditions.

Why it matters：This is the first approved therapy for an ultra-rare, fatal brain disease, showing that decades of basic research can translate into a treatment even when the patient population is tiny; it offers a regulatory and commercial template for other rare neurological disorders.

Key points

  • Alexander disease affects fewer than one in a million people.
  • Zanvastro directly targets the disease rather than only treating symptoms.
  • Clinical trials showed stabilized motor function and improvement in some patients.

Sources (original reporting)

More stories from this day